In terms of treatment response to anti-VEGF or anti-EGFR inhibitors in metastatic CRC, upregulation of miR-126 was correlated with bevacizumab resistance, whereas overexpression of miR-31, miR-100, and miR-125b and downregulation of miR-7 with resistance to cetuximab, respectively [23]. This evidence concerns the gene EGFR and colorectal carcinoma.